The STEP (Semaglutide Treatment Effect in People with obesity) trial program delivered landmark data
Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a holistic weight loss program that combines personalized dosing when clinically necessary, 24/7 care team access, and educational support across nutrition, mental health, and physical wellness
Eli Lillys competing CDK4/6 inhibitor, Verzenio (abemaciclib), and Novartiss Kisqali (ribociclib) face similar timelines, with abemaciclibs core patents expiring in 2028 and ribociclibs in 2027
They are also rich in cysteine, an amino acid that promotes glutathione production
Development of more efficient production methods or alternative formulations may be necessary to address these constraints
Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1